Awarded Grants
Awarded Grants
Identification of vulnerable cell types and quantification of cell type-specific differential gene expression in the Pitt-Hopkins Syndrome mouse model
Brady Maher
Johns Hopkins University School of Medicine
$73,473.00
Awardee: Brady Maher
Institution: Johns Hopkins University School of Medicine
Grant Amount: $73,473.00
Funding Period: February 1, 2024 - January 31, 2025
Summary:
The brain is composed of two major cell types, neurons and glia; however, these two cell classes quickly become very complex as you begin to categorize them into specific subtypes of cells based on their structure and function. For instance, glia cells are comprised of astrocytes, oligodendrocytes, and microglia, which all have unique structures and functions, and these three cell types can be further divided into additional subtypes. This complexity is even greater for neurons, which are first subdivided into excitatory and inhibitory neurons, but then have so many subtypes they cannot all be listed here. Recent technological advances in single cell sequencing (scRNAseq) have emerged that allow us to quantify the expression of genes within individual cell types, which is critically important because each subtype of cell expresses different genes that regulate the specific function of that cell type. Transcription factor 4 (Tcf4), is a transcription factor that regulates expression of specific genes, however the set of genes it regulates, differs depending on the cell type. Currently, there is no data available that describes how disease-causing mutations in TCF4 effects cell type specific expression in the brain. Therefore, we propose to perform scRNAseq on brain samples from the PTHS mouse model and WT littermates. Previous results from our lab and others have shown that Tcf4 is highly expressed during brain development and mutations in Tcf4 result in alterations in the proportions of specific types of cells (e.g., GABAergic interneurons and oligodendrocytes), however we hypothesize this list of vulnerable cell types is not complete. In addition, Tcf4 is expressed throughout the lifespan, where it is continually regulating gene expression in a cell-type dependent manner. Unfortunately, the field currently lacks an understanding of which sets of genes Tcf4 regulates in any specific cell type. Our proposal is designed to fill in these important knowledge gaps and will help to confirm prior observed vulnerable cell types and identify new cell types of risk. In addition, our approach will identify genes that are differentially expressed in specific cell types, which will help to identify genes that can be targeted by cell type-specific therapeutic approaches. We plan to openly share our results with the research community. We believe it will be beneficial to improving emerging gene therapy approaches by informing us about which cell types should be modified. We believe it will serve to identify vulnerable cell types that may in the future be replaced using cell replacement therapies. Lastly, we believe these datasets will be useful for computational approaches that are using artificial intelligence and machine learning paradigms to identify therapeutic targets and predict effective therapeutic compounds.
Development of proof-of-concept Pitt-Hopkins Syndrome therapy by upregulation of TCF4 transcriptional activity
Tonis Timmusk
Tallinn University of Technology
$71,650.00
Awardee: Tonis Timmusk
Institution: Tallinn University of Technology
Grant Amount: $71,650.00
Funding Period: February 1, 2023 - January 31, 2024
Summary:
Pitt Hopkins syndrome (PTHS) is a genetic developmental disorder that severely affects cognitive, motor and social development. PTHS has been diagnosed in less than 1000 people in the world. It is caused by mutations in one of the two alleles of a gene called TCF4, which encodes a protein named Transcription Factor 4. Most of the mutations found in TCF4 gene in PTHS patients are of de novo origin meaning that the mutation is not present in the parents. TCF4, as other transcription factors, is a protein that regulates the expression of genes. In the nervous system TCF4 plays an important role in proliferation, differentiation and migration of neurons, as well as brain plasticity. Upregulation of the transcriptional activity of the functional TCF4 protein could improve the symptoms of PTHS. The goal of the current project is to develop a method to upregulate TCF4 activity levels by targeting TCF4 co-regulators.
Rescuing oligodendrogenesis and myelination as possible treatment for Pitt-Hopkins patients
Simone Mesman
Swammerdam Institute of Life Sciences, University of Amsterdam
$78,530
Awardee: Simone Mesman
Institution: Swammerdam Institute of Life Sciences, University of Amsterdam
Grant Amount: $78,530
Funding Period: February 1, 2022 - January 31, 2023
Summary:
In the brain of Pitt-Hopkins patients myelination, fatty sheets surrounding axons of neurons, is affected. The correct construction of these myelin sheets is crucial for proper brain functioning and neuronal communication. Incorrect myelination generally results in affected brain functioning and could be an underlying cause for defects in brain functioning as detected in PTHS. We propose to study myelination under inflence of PTHS-related Tcf4 mutations, by investigating myelination profiles in PTHS patients and by studying the effects of these mutations on oligodendrogenesis, the generation of oligodendrocytes the cell-type that produces myelin.
Reinstatement of Tcf4 function to treat Pitt-Hopkins Syndrome
Andrew Kennedy
Bates College
$71,643
Awardee: Andrew Kennedy
Institution: Bates College
Award Amount: $71,643
Funding Period: February 1, 2021 - January 31, 2022
Tissue-specific and temporal reinstatement of Tcf4 to treat Pitt-Hopkins Syndrome
Andrew Kennedy
Bates College
$68,709
Awardee: Andrew Kennedy
Institution: Bates College
Award Amount: $68,709
Tissue-specific and temporal reinstatement of Tcf4 function to treat Pitt-Hopkins Syndrome
Andrew Kennedy
Bates College
$51,242
Awardee: Andrew Kennedy
Institution: Bates College
Award Amount: $51,242
Funding Period: February 1, 2019 - January 31, 2020
Pilot study to develop a small molecule activator of TCF4 as a treatment for Pitt-Hopkins syndrome
Ben Philpot
University of North Carolina, Chapel Hill
$51,242
Awardee: Ben Philpot
Institution: University of North Carolina, Chapel Hill
Award Amount: $51,242
Funding Period: February 1, 2019 - January 31, 2020
Pilot study to identify small molecule activators of TCF4 as a treatment for Pitt-Hopkins syndrome
Benjamin Philpot
University of North Carolina, Chapel Hill
$49,263
Awardee: Benjamin Philpot
Institution: University of North Carolina, Chapel Hill
Award Amount: $49,263
Funding Period: January 1, 2018 - December 31, 2018
Epigenetic Therapy to Treat Pitt-Hopkins Syndrome (PTHS)
Andrew Kennedy
Bates College
$49,263
Awardee: Andrew Kennedy
Institution: Bates College
Award Amount: $49,263
Funding Period: January 1, 2018 - December 31, 2018
Identification of direct target genes of TCF4 in neurons
Tonis Timmusk
Tallinn University of Technology
$51,000
Awardee: Tonis Timmusk
Institution: Tallinn University of Technology
Award Amount: $51,000
Funding Period: January 1, 2017 - December 31, 2017
Pharmacological rescue and screening in a Pitt Hopkins model.
Daniel Marenda
Drexel University
$51,000
Awardee: Daniel Marenda
Institution: Drexel University
Award Amount: $51,000
Funding Period: January 1, 2017 - December 31, 2017
Identification of Molecular Targets for Pitt-Hopkins Syndrome Treatments
Benjamin Philpot
University of North Carolina, Chapel Hill
55,000
Awardee: Benjamin Philpot
Institution: University of North Carolina, Chapel Hill
Award Amount: $55,000
Funding Period: January 1, 2015 - December 31, 2015
Understanding TCF4 function in post-mitotic neuron synaptic plasticity
Daniel Marenda
Drexel University
55,000
Awardee: Daniel Marenda
Institution: Drexel University
Award Amount: $55,000
Funding Period: January 1, 2015 - December 31, 2015